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ABSTRACT
Antihypertensive medications have represented a tremendous financial burden to the health care plan globally. The utilization pattern of the antihypertensive agents was examined in this study to analyze the underlying reasons responsible for the pharmaceutical expenditure in Taiwan during 1997 to 2002. The claims data were obtained from National Health Insurance Research
Database (NHIRD), which include ambulatory service record and prescription data of the entire population. Drug expenditure
was decomposed into 5 components: relative drug price, number of patients treated, average physician visit per patient, defined
daily dose (DDD) per physician visit and a residual. Total antihypertensive drug spending increased 102% during this period,
mainly due to the compounding effect from the increment of patients treated (34%) and DDD per physician visit (33%). The
aggregate residual for antihypertensive agents only exerts a 7% effect. Detailed residual analysis revealed that the brand-name
product did have 11% increment, while the generic product had a 12% decrement. It also showed that hospital sector had a
positive 11% residual, while primary care clinics had an 11% decrement. The most important factors that contribute to the expenditure surge of antihypertensive agents are the number of treated patients and DDD per physician visit. While physicians at the
hospital sector adopted more new and innovative medications, their counterparts at the primary care clinics tended to switch some
off-patent products to the generics.
Key words: antihypertensive agent, defined daily dose (DDD), drug utilization, pharmaceutical expenditure, pharmacoeconomics

INTRODUCTION
The beneficial effects of antihypertensive medications on mortality and cardiovascular morbidity are
well documented in the literatures (1-3). However, the
success also poses a tremendous financial burden to the
patients, insurance companies and health care providers.
Facing this dilemma in today’s medical environment, the
economic aspect of the evaluation is gradually gaining
its ground to resolve this issue in recent years(4,5).
The National Health Insurance Program started in
Taiwan, 1995. Taiwan’s healthcare system is mainly
publicly managed by the Bureau of National Health
Insurance (BNHI). It covered 22 million people (98.7%
of the total population) at the end of 2003. The BNHI
contracted with 17,022 (93.8%) medical institutions
nationwide (6). Medical institutions are classified into
4 levels by their size: medical center, regional hospital,
district hospital and primary care clinic. All hospital
* Author for correspondence. Tel: +886-6-2353535 ext. 5688;
Fax: +886-6-2373149; E-mail: yhkao@mail.ncku.edu.tw

settings provide both in-patient hospitalization service
and out-patient ambulatory care service. Patients can
freely choose to go to primar y care clinic or to the
out-patient service of any level of hospital for their ambulatory care with tiered registration fee and co-payment.
The outpatient prescription drug expenditure is covered
by BNHI as part of the benefit package. The national
claim data became available since 1997. It is the first
time in Taiwan for the public to access such a thorough
detailed database. This claim database is licensed to and
administrated by the National Health Research Institute
(NHRI), a non-prof it research organization founded
and sponsored by the Department of Health, and been
referred as National Health Insurance Research Database
(NHIRD). Special request to use data from NHIRD for
research has to be reviewed and approved beforehand.
Gerdtham and his coworkers used the term “residual” to explain the changes in treatment patterns (7-9).
Residual is a factor to adjust the differences between the
existing price/quantity indices and the true price/quantity. An increased residual usually means a shift towards
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more expensive drug treatment and a decreased residual,
on the other hand, means shifting towards less expensive
one. Using this residual analysis, Gerdtham et al. reported a 67% total residual increase during 1990 to 2000
in Sweden (7). Darba also reported a 28% total residual
increase during 1997 to 2001 in Spain(10). Both studies
indicated that the residual was the most important cost
component responsible for the drug expenditure growth
in these two countries during 1990 to 2000. We would
like to investigate whether this situation also occurred in
Taiwan, especially the antihypertensive agents.
Retrospective pharmacoeconomic analysis using
claim database is commonly employed to compare health
costs associated with competing drugs or intervention(11).
Although this scheme is considered to be inferior to
prospective study due to limited patient information in the
claim records, it is far less expensive and thus justifies its
use to extract preliminary useful information for further
study design. In this study, the 1997-2002 ambulatory
service records and prescription claim data files from
the NHIRD were used to analyze the trend of utilization
pattern of antihypertensive agents in Taiwan with the goal
of better understanding the underlying reason(s) for the
pharmaceutical expenditure surge during this period.

MATERIALS AND METHODS
I. Data Collection
All ambulatory antihypertensive medications used
in Taiwan during 1997 to 2002 were obtained from the
NHIRD, which includes ambulator y service records
and prescription claim data. Both files were merged by
patients’ masked codes with an average matching of 99.6%
and a total of 122,397,631 observed data sets for 6,228,094
patients. A total of 1021 antihypertensive products were
included for analysis, and which were identified from the
NHI pharmaceutical reimbursement database. The data
were subsequently grouped by Anatomical Therapeutic
Chemical (ATC) classification system using the National
Health Insurance Pharmaceutical Coding System previously developed by Yang Kao(12). According to the ATC
system, the antihypertensive agents were classified into the
following categories: centrally acting antiadrenergic agents
(C02A), peripherally acting antiadrenergic agents (C02C),
antihypertensives and diuretics in combination (C02L),
agents acting on arteriolar smooth muscle (C02D), combinations of antihypertensives in ATC group C02 (C02N),
low-ceiling diuretics, thiazides (C03A), low-ceiling diuretics, excluding thiazides (C03B), high-ceiling diuretics
(C03C), potassium-sparing agents (C03D), diuretics and
potassium-sparing agents in combination (C03E), beta
blocking agents (BB, C07A), beta blocking agents and
thiazides (C07B), beta blocking agents and other diuretics
(C07C), beta blocking agents, thiazides and other diuretics
(C07D), calcium channel blockers with mainly vascular

effects (CCB, C08C), calcium channel blockers with direct
cardiac effects (C08D), ACE inhibitors (ACEI, C09A),
angiotensin II antagonists (AIIA, C09C), and angiotensin
II antagonists combinations (C09D).
All data were presented in units per year. Consumer product indices were obtained from the website of
Directorate General of Budget, Accounting and Statistics
(DGBAS) of Executive Yuan, Taiwan(13).
II. Method of Analysis
Gerdtham et al. broke down the drug expenditure
into 3 components: price of drugs, the quantity of drugs
consumed and a residual(8) as shown in equation 1:
Real Annual Drug Expenditure = Relative Drug Index ×
Annual Drug Quantity Consumed DDD × Residual Eq. (1)
Relative drug index = drug index at 1997/ consumer price
index, assuming 1997 price equals to 1.00
Gerdtham further decomposed the quantity component DDD into 3 subcomponents: number of DDD per
patient, proportion of the population on medication and
the population size (7). The population size in Taiwan
during 1997 to 2002 remained fairly stable around 22
million with less than 3.6% changes and thus can be
ignored (14). We further modify the “DDD per patient”
into DDD per physician visit times the number of physician visit per patient and “the proportion of the population
on medication” into the number of patients treated with
the medication since all these terms were readily available from the claim database. By decomposing “DDD per
patient” into “DDD per physician visit” and “the number
of physician visit per patient”, we will be able to differentiate whether each patient visit physician more frequently
(patient factor) or the physician had prescribed more
medication (physician factor). If we can find out which
factor is the major one, we shall be able to take proper
measures to control the growth of that factor. The number
of physician visit per patient varies from patient to patient,
so we use the number of total annual physician visits
divided by the number of total patients treated to obtain
“the average physician visit per patient”. Since the total
population in Taiwan remained fairly constant from 1997
to 2002, “the proportion of the population on medication”
used in Gerdtham’s study could be converted into “number
of patients treated with the medication” by multiplying
the total population with the proportion of the population on medication. Therefore, the annual drug quantity
consumed can still be decomposed into 3 subcomponents
and be expressed as follows:
Annual Drug Quantity (DDD) = No. of annual treated
patients × Ave. physician visit/patient/year × DDD/physician visit
Eq. (2)
Substitute Equation 2 into Equation 1,
Real Annual Drug Expenditure
= Relative Drug Index × No. of annual treated patients ×
Ave. physician visit/patient/year × DDD/physician visit ×
Residual
Eq. (3)
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ANOVA F-test was used to compare percentage of total expenditure each year.

1,375,357,603 (12.83) 2,048,448,886 (17.21) <0.001b
859,341,339 (9.10)
469,626,237 (5.30)

b

Chi-square test was used to compare gender each year.

Angiotensin II antagonists

0

(0.00)

83,444,401 (1.14)
a

1,715,810,129 (29.12) 2,109,744,469 (28.76) 2,337,574,910 (26.40) 2,277,668,318 (24.18) 2,358,034,960 (22.00) 2,306,151,809 (19.37) <0.001b
ACE inhibitors

0.001b
2,522,120,514 (42.80) 3,124,368,581 (42.59) 3,597,835,899 (40.63) 3,741,400,583 (39.72) 4,202,028,177 (39.20) 4,576,013,448 (38.44)
Calcium channel blockers

0.002b
1,135,364,527 (19.27) 1,366,406,011 (18.63) 1,653,771,792 (18.68) 1,715,953,044 (18.22) 1,871,214,687 (17.45) 1,984,213,988 (16.67)

208,095,076 (3.53)
Diuretics

β-Blocking agents

0.132b
455,917,291 (3.83)
406,087,776 (3.79)
369,500,385 (3.92)
345,964,135 (3.91)

454,620,002 (4.83)
450,286,862 (5.09)
392,790,577 (5.35)
311,571,624 (5.29)
Anti-adrenergic agents

259,401,963 (3.54)

0.001b
533,275,992 (4.48)
507,943,029 (4.74)

11,904,021,414
10,720,666,232
9,418,483,671
8,855,059,835
7,336,156,002
5,892,961,870
Total expenditure of each category (%)

0.30
Unknown (%)

Total drug expenditure (NTD)

46.22

0.51
0.48

46.05
45.93

0.39
0.38

45.83
45.91
Male (%)

0.46

53.48
53.68
53.79
53.80
53.79
Female (%)

45.74

53.26

56.75 ± 16.93
56.44 ± 16.91
56.22 ± 17.00
55.47 ± 17.41
55.51 ± 17.67
55.36 ± 17.50

21,206,820

2,891,479
2,650,132

Patient Visits

19,194,467

2,328,204

16,073,491

Patient

1998
1997

Table 1. Demographics and pharmaceutical cost of antihypertensive agents during 1997 to 2002

The average age of the patients taking antihypertensive medication during this period was 56.0 ± 17.2. Age
60 to 70 represented the major patient group with 23.32 ±
0.98% of the total patient population. Female was statistically more than male (53.63 ± 0.22% vs. 45.95 ± 0.17%;
p < 0.01). The absolute amount of money spent (nominal
drug expenditure) for all the antihypertensive medication
from 1997 to 2002 increased from 5.89 billion NTD to
11.90 billion NTD (Table 1). A linear regression analysis
revealed an annual growth rate of 19.9% (R 2 = 0.99, p <
0.001). The average nominal annual pharmaceutical cost
per patient taking antihypertensive medication increased
from 2,531 NTD at 1997 to 3,817 NTD at 2002, a 51%
increment. Patient demographics and pharmaceutical cost
by pharmacological class of drug are presented in Table 1.
The nominal pharmaceutical expenditure was first
normalized with consumer product index and further
decomposed into relative drug price, quantity prescribed
DDD and a residual according to the equation 1. Among
the three components, DDD demonstrated an increment
of 91% as shown in Table 2. The number of patients
treated with antihypertensive agents annually, average of annual physician visits per patient and DDD per
physician visit were presented in Table 3. Although the
physician visits per patient had increased only 7% during
the six-year period, the number of patients and DDD per
physician visit had raised 34% and 33%, respectively.
This 34% increment from patient growth is an intrinsic
growth and is usually very hard to control. The 33%
increase of DDD per physician visit may result from
prescribing behavior change and could be corrected
through education or other financial incentives. Detailed
analysis of the DDD for each sub-pharmacological group

1999

RESULTS

Gender

3,034,745
2,892,826

20,296,332

2000

2001

All data analysis was performed using SAS package (Windows Release 8.02 version TS Level 02M0)
from SAS Institute Inc. (Cary, NC, USA). Chi-square
test was used to compare nominal variable and data were
considered statistically significant at p < 0.05. For linear
regression analysis, the least-squares method of best fit
curve was done using the analytical tools provided by
Microsoft ® Office Excel 2003 (Redmond, WA, USA).
Analysis of variance (ANOVA) was computed to test the
secular correlation of pharmaceutical expenditure.

22,024,726

III. Statistical Analysis

Mean Age (± SD)

3,118,601

23,063,913

2002

p value

Monetary unit used in this study is the local currency, NTD. The exchange rate for NTD to USD is between
28.66 and 34.58 during this period (15). With more than
20% variation on the exchange rate, NTD was chosen
to report the data to avoid the deviation of the raw data
since all claims and reimbursements were made in NTD.
All data were standardized to 1997 value equal to 1.00.

<0.001a
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Table 2. Indices of nominal drug expenditure, real drug expenditure, relative drug price, DDD and the residual during 1997 to 2002. All
measurements and calculations were standardized to 1997 = 1.00

a

Year

Nominal drug exp.

Real drug exp.a

Relative drug pricea

DDD

Residual

1997

1.00

1.00

1.00

1.00

1.00

1998

1.24

1.22

0.98

1.24

1.00

1999

1.50

1.47

0.98

1.45

1.03

2000

1.62

1.55

0.97

1.52

1.05

2001

1.82

1.76

0.97

1.74

1.04

2002

2.02

1.96

0.97

1.91

1.06

Nominal drug expenditure or drug price divided by consumer price index.

Table 3. Indices of antihypertensive DDD, number of treated
patients, average number of physician visit per patient and DDD per
physician visit during 1997 to 2002. All measurements and calculations were standardized to 1997 = 1.00
Year

DDD

Treated
patient

No. of physician
visit/patient

DDD/physician
visit

1997

1.00

1.00

1.00

1.00

1998

1.24

1.14

1.05

1.04

1999

1.45

1.24

1.06

1.10

2000

1.52

1.24

1.02

1.20

2001

1.74

1.30

1.05

1.27

2002

1.91

1.34

1.07

1.33

of the antihypertensive agents was presented in Table
4. Detailed analysis of the residual for each sub-pharmacological group of the antihypertensive agents was
presented in Table 5. Significant changes were observed
in several sub-groups such as combinations of antihypertensives in ATC group C02 (C02N) (68% decrement)
and high-ceiling diuretics (C03C) (33% increment).
With such dramatic changes in the sub categories, they
contributed little to the overall residual due to the relative small DDD changes. Residual analysis, which was
performed on the brand name products vs. locally manufactured generic products as well as on the hospital and
primary care sectors, demonstrated 11% increment of the
brand name products and the hospital sectors (Table 6).

DISCUSSION
Cheng and Hsieh had reported that, during 1996 to
2002, the average annual growth rate on Taiwan’s total
National Health Insurance drug expenditure was 6.4%(16).
However, the expenditure of antihypertensive drug was
increased from 5.89 billion NTD to 11.90 billion NTD
from 1997 to 2002 in this study, which indicated that the
rate of the antihypertensive drug expenditure in Taiwan
grew at almost twice faster than that of the average drug
expenditure.

I. Decomposition of Drug Expenditure Component
The substantial increase in real drug expenditure
(96%), which had adjusted for inf lation, is mainly due
to the growth of DDD (91%) and the trend of growth
is almost identical as shown in Table 2. In contrast to
the drug expenditure and DDD, the relative drug price
decreased a negligible 3% in this period. The residual
was also a minor contributor with only 6% growth in
6 years in our study. The term, “residual”, is used to
explain the remaining part of real drug expenditure not
accountable by relative drug price and quantity (7,8,10).
It is a measure of the impact of changes in drug treatment/utilization pattern on drug expenditure. This is
not to say that there were no or very few innovative and
new medications introduced into the market at this time.
As a matter of fact, quite a few new and significantly
improved medications were launched and subsequently
widely accepted by physicians during this period such as
Angiotensin II antagonist (AIIA) and long-acting calcium channel blocker (CCB).
II. Decomposition of Quantity Component
Since the major contributor for the expenditure
growth of antihyper tensive agents is the DDD, this
component is further decomposed into 3 subcomponents
as listed in equation 2 and shown in Table 3. The average
DDD per physician visit increased from 23.14 to 30.79 in
this period. The average number of physician visits per
treated patient remains fairly constant for the whole period
with the range of 6.9 to 7.4 visits per patient per year.
Therefore, the average DDD per treated patient increased
from 159.8 at 1997 to 227.7 at 2002, a 42% increment,
which was the product from the average DDD per physician visit and number of physician visit per patient (data
on file). The number of physician visit per patient using
antihypertensive medication in this study from NHI database is much higher than the average number of physician
visit per patient per claim year in Japan (taking all medications into account) during 1979 to 1993(17). The higher
frequency of physician visit in Taiwan could be caused by
convenient accessibility to health care organizations as
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Table 4. DDD for total and each sub-group antihypertensive drugs during 1997 to 2002
Year

1997

1998

1999

2000

2001

2002

Pharmcological
category
C02A

1,281,385

1,120,161

1,033,503

859,912

815,251

737,447

C02C

8,476,959

11,004,122

13,026,495

13,415,840

15,493,811

16,640,936

C02D

4,392,746

4,027,335

3,749,985

3,041,983

2,780,360

2,436,731

C02L

8,053,730

8,954,631

9,099,353

8,172,606

7,746,674

7,094,360

C02N

7,574

6,601

9,346

5,844

3,661

4,383

C03A

16,233,615

17,704,231

18,539,495

17,783,241

18,681,218

18,416,304

C03B

4,650,203

6,806,295

12,046,063

14,140,979

16,006,696

17,775,024

C03C

18,525,906

22,103,634

24,388,483

24,958,295

27,514,120

29,879,147

C03D

3,220,575

3,654,871

4,148,376

4,527,163

5,249,424

5,702,917

C03E

9,649,576

11,543,994

12,087,818

11,633,341

12,272,230

12,399,447

C07A

90,159,907

107,145,247

121,214,655

122,389,555

134,691,460

139,514,422

C07B

309,370

268,146

87,036

2,359

926

163

C07C

2,054,664

2,518,202

2,248,866

1,974,825

2,132,381

2,148,212

C07D

4,302

2,552

7,328

291

0

0

C08C

98,078,863

127,204,075

151,218,647

161,195,785

190,167,505

215,155,723

C08D

15,367,356

17,535,780

18,785,188

18,583,598

20,546,996

21,140,854

C09A

91,510,909

115,832,460

130,770,657

130,777,000

142,048,356

145,867,836

C09C

0

2,853,253

16,236,910

30,686,995

49,871,875

72,223,464

C09D
TOTAL

0

0

0

0

277,181

2,926,387

371,977,726

460,285,675

538,698,290

564,149,699

646,023,031

707,137,461

C02A: antiadrenergic agents, centrally acting;
C02C: antiadrenergic agents, peripherally acting;
C02D: arteriolar smooth muscle, agents acting on;
C02L: antihypertensives and diuretics in combination;
C02N: combinations of antihypertensives in ATC-gr. C02;
C03A: low-ceiling diuretics, thiazides;
C03B: low-ceiling diuretics, excl. thiazides;
C03C: high-ceiling diuretics;
C03D: potassium-sparing agents;
C03E: diuretics and potassium-sparing agents in combination;
C07A: beta blocking agents;
C07B: beta blocking agents and thiazides;
C07C: beta blocking agents and other diuretics;
C07D: beta blocking agents, thiazides and other diuretics;
C08C: selective calcium channel blockers with mainly vascular effects;
C08D: selective calcium channel blockers with direct cardiac effects;
C09A: ACE inhibitors, plain;
C09C: angiotensin II antagonists, plain;
C09D: angiotensin II antagonists, combinations.

well as lower pharmaceutical amount prescribed of each
visit. However, it is still reasonable in this situation since
most of the cardiovascular diseases are chronic illnesses
that need constant medication treatment. The fact that
prescription refill practice is not well established in
Taiwan also plays an important role. The other 2 components, number of patients treated and DDD per physician
visit, are equally important contributors to the growth of
DDD in this period with 34% and 33% increment, respec-

tively. The compounding power of increasing patients and
DDD per visit resulted in the substantial growth of the
observed DDD during this period.
The number of patients treated grew faster from
1997 to 1999, and slowed down afterwards. This organic
growth is more on the demand side and may be due
to easier patient accessibility, more elder population,
etc. Different means have been proposed to reduce this
demand by either denying or limiting reimbursement
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Table 5. Indices of residual for total and each sub-group antihypertensive drugs during 1997 to 2002. All calculations were standardized to
1997 = 1.00
Year

1997

1998

1999

2000

2001

2002

C02A

1.00

1.09

1.08

1.10

1.15

1.17

C02C

1.00

1.07

1.10

1.12

1.13

1.13

C02D

1.00

0.99

0.96

0.98

0.97

1.02

C02L

1.00

0.99

0.96

0.95

0.91

0.91

C02N

1.00

0.78

0.53

0.47

0.34

0.32

C03A

1.00

0.98

1.00

1.01

0.98

0.97

C03B

1.00

0.99

0.98

0.95

0.93

0.96

C03C

1.00

1.03

1.10

1.06

1.15

1.33

C03D

1.00

0.99

0.98

0.99

0.94

0.91

C03E

1.00

0.98

0.96

0.96

0.95

0.93

C07A

1.00

1.01

1.08

1.13

1.12

1.15

C07B

1.00

1.01

0.94

0.88

0.91

0.88

C07C

1.00

0.95

0.89

0.85

0.86

0.88

C07D

1.00

0.96

1.01

0.99

-

-

C08C

1.00

0.97

0.96

0.95

0.91

0.89

C08D

1.00

1.00

0.98

0.96

0.91

0.89

C09A

1.00

0.97

0.95

0.93

0.89

0.84

Pharmcological
category

C09C

-

1.00

0.99

0.96

0.94

0.93

C09D

-

-

-

-

1.00

0.99

TOTAL

1.00

1.01

1.03

1.05

1.05

1.06

Pharmacological category is noted as in Table 4.

Table 6. Indices of residual for total, brand, generic antihypertensive drugs, clinics and hospital sector during 1997 to 2002. All calculations
were standardized to 1997 = 1.00
Year

Total

Brand

Generic

Clinics

Hospital

1997

1.00

1.00

1.00

1.00

1.00

1998

1.03

1.02

1.00

0.99

1.02

1999

1.05

1.05

1.00

0.96

1.07

2000

1.05

1.08

0.97

0.95

1.10

2001

1.05

1.09

0.92

0.92

1.09

2002

1.06

1.11

0.88

0.89

1.11

of pharmaceutics through co-payment, co-insurance
or deductible and providing an incentive for patients
to reduce their consumption of dr ugs (16,18-20) . Drug
co-payment scheme was first implemented at August
1998 in Taiwan with a 100 NTD drug co-payment ceiling
per physician visit. The co-payment ceiling was further
raised to 200 NTD per physician visit at September 2002
to control drug expenditure growth (15). This intervention may have some inf luence on slowing down the
patient growth after 1999. However, it had little effect
on the total expenditure growth of antihypertensive

drugs due to the DDD per physician visit growth. This
result is similar to that obtained by other researchers
from the drug co-payment program(18,19). It agrees with
other researchers’ conclusion that it is hard to control the
demand side growth.
While residual reflects the direction of drug utilization shift, DDD per physician visit reflects the magnitude
of drug utilization. DDD per physician visit increased
from 23.14 at 1997 to 30.79 at 2002. It had a slow increment rate from 1997 to 1999, and then grew much faster
afterwards. We further analyze the individual DDD per
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CCB

ACEI

BB

AIIA

Other

TOTAL

35
y (Total) = 1.76 x + 22.20
R 2 = 0.99  p < 0.001

DDD/physician visit

physician visit from 4 of the most prescribed sub-groups
of the antihyper tensive agents-angiotensin conver ting enzyme inhibitor (ACEI), β-blocker (BB), calcium
channel blocker (CCB) and angiotensin II antagonist
(AIIA), which accounts for approximately 75-80% of all
antihypertensive agents prescribed in this period (data
on file), and others. The result of the least-squares best
fit curves for total, individual sub-group and others for
1998 to 2002 is shown in Figure 1. The best fit curve for
the total DDD per physician visit showed a linear growth
with 1.76 increment per year and R 2 = 0.99. DDD per
physician visit for ACEI and CCB shared similar linear
annual growth pattern with 1.51 and 1.41 increment per
year and R 2 = 0.98 and 0.98, respectively. DDD per
physician visit for BB remained fairly constant around
14 with a parabolic curve during this period (R 2 = 0.93).
AIIA, a new pharmacological class of antihypertensive
drugs introduced into Taiwan’s market in the first quarter of 1998, accounted for 12% of the total antihypertensive DDD at the 4th quarter of 2002 (data on file). It
showed a parabolic growth pattern with a plateau at 27
on 2001, 4 years after its launch. The best fit curve for
it is y = -0.437 x 2 + 3.96 x + 18.3 with R 2 = 0.999. The
rest of 15 other sub-groups (as called others) had a flatter
linear growth with 0.66 annual increment and R 2 = 0.99.
It is reported by other researchers that BB, ACEI, CCB
and diuretics were the most prescribed antihypertensive
drugs in the medical institutions in Taiwan at 1998(21,22).
Apparently, AIIA has replaced diuretics as the fourth
most prescribed since its introduction. It is also reported
that patients initially prescribed with AIIA were more
persistent in Italy(23).
Policies intended to affect physicians’ prescribing behaviors including clinical guidelines, generic
substitution incentive, restrictive formularies, physician prescription feedback system and the use of budget
control(16,20,24,25). Under previous fee-for-service environment in Taiwan, generic substitution did not offer
much incentive for the physician or hospital administrator
to change the prescribing pattern or purchasing decision
since the physician or hospital would get full reimbursement from BNHI. Generic substitution, therefore, did not
have much impact in reducing the total drug expenditure.
In fact, the monetary market share for antihypertensive
generics actually decreased from 26.7% at 1997 to 21.5%
at 2002, representing a relative 19.5% market share loss
during this period (data on file). This number is even less
than that in India (30%) (26). Clinical guidelines along
with a systematic feedback peer review system may be a
feasible approach to restrict the growth of DDD per visit
to an acceptable range (25). Global budget control was
implemented at the primary care clinics on July 2001 and
at the hospital sector on July 2003. The impact on the
expenditure of antihypertensive drug remains to be seen
in the future when the data become available and warrants
further investigation.

30

y (ACEI) = 1.51 x + 23.14
R 2 = 0.98  p = 0.001
y (AIIA) = 0.43 x 2 + 3.96 x + 18.30
R 2 = 0.99

25
20

y (CCB) = 1.41 x + 18.01
R 2 = 0.98  p = 0.001
y (BB) = 0.29 x + 13.39
R 2 = 0.93  p = 0.007

15

y (Other) = 0.66 x + 11.77
R 2 = 0.99  p < 0.001

10
1998

1999

2000

2001

2002

Figure 1. The least-squares best fit curves of DDD per physician
visit for total antihypertensive drugs, ACEI, AIIA, BB, CCB and
others in Taiwan during 1998 to 2002.

III. Demographic Residual Analysis
Detailed analysis of the residual for each sub-pharmacological group of the antihypertensive agents was
performed to check whether there is a drug utilization
shift within the entire group. The result is presented
in Table 5. Though the aggregate residual did not vary
much du r ing this per iod, sig nif icant changes were
obser ved in several sub-groups such as C02N (68%
decrement) and C03C (33% increment). Thirteen out
of 19 groups showed decreased residual and the other
6 groups had increased residual. Among 4 of the most
frequently prescribed sub-groups, ACEI, AIIA and CCB
showed decreased residual (16%, 7% and 11%, respectively) and only BB had a 15% residual increment. The
decrement could not totally be explained by the generic
substitution. For example, there is no generic product
available for AIIA at this time; however, it still had a 7%
residual decrement (Table 5, C09C). This indicated that
pricing control policy adopted by Taiwan’s BNHI during
this period such as pharmaceutical grouping and implementation of reasonable-zone-pricing did have some
success in controlling the pharmaceutical expenditure.
Further analysis on the residuals for two sub groups
were performed to reveal the relationship between the
number of drug pricing change and the magnitude of
residual. The 33% C03C residual increment came from
the combinational effect of 5 drug pricing increment, 11
pricing cut and 37 unchanged prices during the period. On
the other hand, the 16% C09A residual decrement came
from the effect of 6 pricing increment, 52 pricing cut and
32 unchanged prices (both data sets on file). This result
indicated that residual, as defined as a factor to adjust the
difference of the existing price and quantity indices and
the true quantity and price, is a very complex factor.
AIIA was introduced into Taiwan’s market in the
first quarter of 1998. It, therefore, was not included in
the 1997 base. By far, AIIA is one of the newest pharma-
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cological classes introduced during this period (the other
one is the combination of AIIA and diuretics) and also
one of the most expensive medication in the entire antihypertensive agents. With its approximately 60% pricing
premium over the average price of all antihypertensive
agents and more than 10% of the total DDD consumed at
2002 (data on file), the introduction of AIIA did have an
impact to the drug utilization shift. It, therefore, partially accounts for the increased aggregate residual while
most of the sub-groups showed decreased residual.
Using residual analysis on the brand name products
vs. locally manufactured generic products as well as on
the hospital and primary care sectors, their effect on
utilization pattern can be quantified. With the introduction of AIIA and long-acting CCB into the market, it is
not surprising to see the increased residual for the brand
name products (11% increment). On the other hand,
quite a few off-patent ACEI and CCB brand name products were replaced by the generic counterparts. With
more generic products competing with each other and
the pricing cut from the BNHI, it is expected to have a
12% decrement on the residual of generic products. This
analysis also demonstrated that physicians at primary
care clinics had a different dr ug utilization pattern,
ref lected by an 11% decrement on the residual value,
from their counterparts at hospitals as ref lected by an
11% increment on the residual.
IV. Limitation
This study was performed based on the most recent
available claim data from the NHIRD. In general, health
resource allocation is better measured or evaluated by
financial amount rather than by volume serviced (11) .
Therefore, these claim data focus more on the financial
and administrative aspect than on the clinical aspect.
Patient profile, for example, only includes age, sex and
demographic information for administrative purpose.
Relationship between patients such as family members
or family history was not released from this database.
The retrieval of the data for a particular group of patients
is generally obtained through logistic parameters such as
geographical or institutional setting(27). Pharmaceutical
expenditure and drug utilization pattern are, however,
inf luenced by multiple variables. Patients’ accessibility, patient population profile, physician profile, hospital
scale, introduction of new innovative chemical compound
or generic products, pharmaceutical marketing effort
toward physician or patient, drug approval process, drug
pricing and reimbursement policy, pattern of persistence
in using medications, number of prescribed medication
classes, specific medication at enrollment, etc. are just
a few variables that are interwoven together (19). Information regarding some of the above factors is generally
limited or not available at all. Other limitations for database studies includes: data quality, sources of bias, population characteristics, fishing for significance, cohort

characteristics and outcomes (27) . What we obtained
from the claim database in this case merely represents
the final result of the time trend of the pharmaceutical
expenditure in the “real world” environment. We could
only try to analyze these data through macroscopic point
of view. A lot of micro factors then would be grouped
into residual or treated patient growth.

CONCLUSIONS
By decomposi ng t he d r ug expe nd it u re i nt o 5
components, we were able to identify the 2 major factors
that contribute to the expenditure surge of antihypertensive drug during 1997 to 2002 in Taiwan, namely number
of patients treated with the antihypertensive agents and
DDD per physician visit. This result suggests that the
demand side (or induced demand) is the major concern
that is wor th more st udy or more st rict reg ulation.
Despite of many new, innovative and expensive antihypertensive agents launched during 1997 to 2002, the
aggregate residual remained very stable with an average
annual growth of 1%. This result clearly demonstrates
that the drug price is not the major factor for overall
rising pharmaceutical expenditure.
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